<DOC>
	<DOCNO>NCT03090880</DOCNO>
	<brief_summary>Prospective randomize open multicenter trial blind adjudication endpoint assess efficacy six-month low-dose LMWH prevention symptomatic incidental VTE patient stage IV lung cancer elevate D-dimer .</brief_summary>
	<brief_title>Prophylaxis Venous Thromboembolism Advanced Lung Cancer ( PROVE )</brief_title>
	<detailed_description>Adult patient age ≥ 18 year stage IV lung cancer elevate D-dimer randomized experimental control group.Patients control group receive usual care , patient experimental group receive subcutaneous tinzaparin daily six month . Follow-up visit take place outpatient clinic day 90 , day 180 day 360 . Blood sample biomarkers perform inclusion visit day 90 .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<criteria>Age ≥ 18 year Social security affiliation Written inform consent Histologically confirm stage IV ( M1a M1b ) nonsmallcell lung cancer , include recurrent nonsmallcell lung cancer period complete remission Ddimer &gt; 1,500 µg/L Planned ongoing chemotherapy target anticancer therapy ECOG 02 Life expectancy &gt; 3 month Hypersensitivity heparin History heparininduced thrombocytopenia Ongoing anticoagulant treatment VTE inclusion Creatinin clearance &lt; 30 mL/min Active bleed Platelet count &lt; 100,000 G/L inclusion Severe hepatic insufficiency Cancer treat exclusively supportive care Previous inclusion trial Aspirin daily dosage &gt; 160 mg Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Low-molecular-weight Heparin</keyword>
	<keyword>Tinzaparin</keyword>
</DOC>